- Record: found
- Abstract: not found
- Article: not found
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study
M.E. Pavel ,
E. Baudin ,
K.E. Öberg ,
J.D. Hainsworth ,
M. Voi ,
N. Rouyrre ,
M. Peeters ,
D.J. Gross ,
J.C. Yao
July 2017
July 2017
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
In the phase 3 RADIANT-2 study, everolimus plus octreotide long-acting repeatable
(LAR) showed improvement of 5.1 months in median progression-free survival versus
placebo plus octreotide LAR among patients with advanced neuroendocrine tumors associated
with carcinoid syndrome. The progression-free survival P-value was marginally above
the prespecified threshold for statistical significance. Here, we report final overall
survival (OS) and key safety update from RADIANT-2.